ANAL CARCINOMA

This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to the usual chemotherapy and radiation treatment can help people with locally advanced anal cancer stay cancer-free longer. The study includes about 180 adults with stage IIB–IIIC anal cancer. Partici…

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This study compares different ways to collect anal cell samples and different HPV tests to see which combination best predicts high-grade anal dysplasia, a pre-cancerous condition. Researchers are enrolling men who have sex with men, including those with and without HIV. The goal…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…

This study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …